Phylinda L S Chan

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 31:243-68. 2004
  2. ncbi request reprint Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 32:307-31. 2005
  3. ncbi request reprint Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 32:459-84. 2005
  4. pmc A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects
    Phylinda L S Chan
    Pharmacometrics, Pfizer Global R and D, Sandwich, UK
    Br J Clin Pharmacol 65:76-85. 2008
  5. pmc The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
    Phylinda L S Chan
    Global Pharmacometrics, Pfizer Primary Care Business Unit, Sandwich, Kent, UK
    J Pharmacokinet Pharmacodyn 38:41-61. 2011
  6. ncbi request reprint Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    Pharm Res 24:791-802. 2007
  7. ncbi request reprint Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments
    Nicholas H G Holford
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 33:281-311. 2006
  8. pmc Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C
    Hannah M Jones
    Pfizer Worldwide R and D, Department of Pharmacokinetics, Dynamics and Metabolism, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
    Br J Clin Pharmacol 73:77-92. 2012

Detail Information

Publications8

  1. ncbi request reprint Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 31:243-68. 2004
    ..The maximum levodopa induced response after the drug holiday is a result of lowered baseline tapping due to the loss of long-duration response and not due to a change in levodopa pharmacokinetics or pharmacodynamics...
  2. ncbi request reprint Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 32:307-31. 2005
    ..Variability in levodopa pharmacokinetic parameters (particularly V1) may result in variability in plasma levodopa concentrations that could contribute to fluctuations in motor response...
  3. ncbi request reprint Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 32:459-84. 2005
    ....
  4. pmc A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects
    Phylinda L S Chan
    Pharmacometrics, Pfizer Global R and D, Sandwich, UK
    Br J Clin Pharmacol 65:76-85. 2008
    ....
  5. pmc The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
    Phylinda L S Chan
    Global Pharmacometrics, Pfizer Primary Care Business Unit, Sandwich, Kent, UK
    J Pharmacokinet Pharmacodyn 38:41-61. 2011
    ..This was not possible with the FOCEI method (NONMEM version VI or below). SAEM provides a more feasible alternative to FOCEI when facing lengthy computation times and convergence problems with complex models...
  6. ncbi request reprint Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation
    Phylinda L S Chan
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    Pharm Res 24:791-802. 2007
    ..To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial...
  7. ncbi request reprint Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments
    Nicholas H G Holford
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 33:281-311. 2006
    ..We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression...
  8. pmc Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C
    Hannah M Jones
    Pfizer Worldwide R and D, Department of Pharmacokinetics, Dynamics and Metabolism, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
    Br J Clin Pharmacol 73:77-92. 2012
    ....